Indren

Zolpidem Tartrate, the active ingredient in Indren, is a non‑benzodiazepine hypnotic (Z‑drug) presented as an oral dosage form for oral use. It is indicated for the short‑term treatment of insomnia in adults. The medication works by enhancing GABA‑mediated inhibition, helping patients fall asleep faster and maintain sleep through the night.

GNH USA supplies Indren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and regulatory compliance. Our distribution network ensures timely delivery to diverse healthcare settings.

Zolpidem Tartrate is used to treat insomnia by facilitating sleep initiation and maintenance.

Insomnia (sleep onset): reduces the time needed to fall asleep. Insomnia (sleep maintenance): decreases the number of nocturnal awakenings. Insomnia (overall sleep quality): increases total sleep time and improves sleep efficiency.

Zolpidem Tartrate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Somnolence or daytime sleepiness - Nausea

Serious or Rare Side Effects: - Complex sleep behaviors such as sleepwalking or driving while not fully awake - Allergic reactions including rash, swelling, or anaphylaxis - Mood changes including depression, anxiety, or suicidal thoughts

When prescribing Zolpidem Tartrate, several safety considerations should be observed.

- Avoid use with alcohol: increased risk of profound central nervous system depression. - Use caution in hepatic impairment: reduced clearance may raise drug exposure. - Do not operate machinery or drive: residual sedation can impair performance the next day. - Pregnancy and lactation: consult a physician as safety data are limited. - Elderly patients: higher susceptibility to falls and cognitive impairment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Zolpidem Tartrate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Alcohol: additive CNS depression may cause severe sedation. - Other CNS depressants (e.g., benzodiazepines, opioids): risk of profound respiratory depression and profound sedation. - Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): can markedly increase zolpidem plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine, phenytoin): may reduce zolpidem levels and diminish efficacy. - Fluvoxamine: may modestly increase zolpidem exposure, requiring dose assessment. - Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine or sertraline: may enhance sedative effects.